Table 5.
Percentages Application of Different Antibiotic Therapy in PNM Patients
| Application | Antibiotics | All Patients | Non-Survivors | Survivors | P |
|---|---|---|---|---|---|
| Antibiotic prophylaxis(698) | Cefuroxime | 393(56.3%) | 41(56.9%) | 352(56.2%) | 0.999 |
| Ceftriaxone | 206(29.5%) | 15(20.8%) | 191(30.5%) | 0.102 | |
| Cefotaxime | 34(4.9%) | 10(13.9%) | 24(3.8%) | 0.001 | |
| Others | 65(9.3%) | 6(8.3%) | 59(9.4%) | 0.999 | |
| Empirical therapy(794) | Ceftriaxone | 54(6.8%) | 6(5.6%) | 48(7.0%) | 0.685 |
| Cefuroxime | 77(9.7%) | 6(5.6%) | 71(10.3%) | 0.160 | |
| Meropenem | 46(5.8%) | 4(3.7%) | 42(6.1%) | 0.383 | |
| Vancomycin | 27(3.4%) | 4(3.7%) | 23(3.3%) | 0.777 | |
| Vancomycin + Meropenem | 288(36.1%) | 29(26.9%) | 259(37.6%) | 0.031 | |
| Cefuroxime + Vancomycin + Meropenem | 32(4.0%) | 7(6.5%) | 25(3.6%) | 0.184 | |
| Others | 273(34.3%) | 52(48.1%) | 221(32.1%) | 0.002 | |
| Precise therapy(769) | Vancomycin | 33(4.3%) | 1(0.9%) | 32(4.9%) | 0.440 |
| Meropenem | 57(7.4%) | 6(5.4%) | 51(7.8%) | 0.440 | |
| Vancomycin + Meropenem | 353(45.9%) | 41(36.6%) | 312(47.5%) | 0.073 | |
| Cefotaxime + Vancomycin + Meropenem | 28(3.6%) | 7(6.3%) | 21(3.2%) | 0.165 | |
| Cefuroxime + Vancomycin + Meropenem | 32(4.2%) | 7(6.3%) | 25(3.8%) | 0.301 | |
| Others | 266(34.6%) | 50(44.6%) | 216(32.9%) | 0.018 |